weight loss response to semaglutide in postmenopausal women Woman shares journey of and gain after using Should postmenopausal women use injectable

Ask for the pharmacy name and whether they operate as a 503A compounding pharmacy or a 503B outsourcing facility - the distinction matters significantly given the FDA's April 2026 regulatory proposal

Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks

If you have heart or kidney disease or are on fluid restriction, follow your healthcare professional's specific guidance

In one study, users lost 29.45% more weight following a 1 mg/week dosage compared to 0.5 mg/week (26)